Connect with us

Australia

THC Global rises with medicinal cannabis product now available via prescription in Australia

THC Global Group Ltd (ASX:THC) has been as much as 18% higher on confirmation that its first Australian-produced medicinal cannabis product is now available for prescription to Australian patients under Australias existing Special Access Schemes.

Full-spectrum medicines are in high demand for prescribers and patients seeking benefit of minor cannabinoids, terpenes and flavonoids which may provide different therapeutic outcomes.

The product is manufactured from cannabis plant material cultivated at THC Globals Bundaberg facility.

“A real milestone”

THC Global chief executive officer Ken Charteris said: “Getting our wholly Australian medicinal cannabis product to be available for prescribing by Australian doctors is a real milestone for THC Global.

“We look forward to increasing the number of Australian patients able to access medicinal cannabis medicines by providing an affordable medicine and supporting both patients and prescribers in the legal and safe use of these products.”

S..

THC Global Group Ltd (ASX:THC) has been as much as 18% higher on confirmation that its first Australian-produced medicinal cannabis product is now available for prescription to Australian patients under Australias existing Special Access Schemes.

Full-spectrum medicines are in high demand for prescribers and patients seeking benefit of minor cannabinoids, terpenes and flavonoids which may provide different therapeutic outcomes.

The product is manufactured from cannabis plant material cultivated at THC Globals Bundaberg facility.

"A real milestone"

THC Global chief executive officer Ken Charteris said: “Getting our wholly Australian medicinal cannabis product to be available for prescribing by Australian doctors is a real milestone for THC Global.

“We look forward to increasing the number of Australian patients able to access medicinal cannabis medicines by providing an affordable medicine and supporting both patients and prescribers in the legal and safe use of these products.”

Shares were as much as 18% higher to 39 cents and are up from 19.5 cents at close on March 30.

The full-spectrum cannabidiol (CBD) medicine launched under the Canndeo brand has been produced entirely in Australia using cannabis sourced from the Bundaberg cultivation facility and manufactured at the companys Southport Facility.

This facility is fully licensed by the Therapeutic Goods Administration (TGA) as meeting Good Manufacturing Practice (GMP) – enabling future export of these products as EU GMP medicines.

CanndeoCare team


The companys medical and clinical affairs team, CanndeoCare, will support doctors, pharmacists and other healthcare professionals in the prescription of these medicines.

They are equipped to provide expert advice and guidance on the technical and medical aspects of medicinal cannabis patient management.

Additionally, Tetra Health, the companys recently acquired clinic network, will enable its network of referring and prescribing physicians to access this new medicine.

Canndeos CBD medicine now available for prescription.Read More – Source

Continue Reading

Australia

Minotaur Exploration enhances share purchase plan to $2.1 million following strong investor demand

Minotaur Exploration Ltd (ASX:MEP) has scaled back its share purchase plan (SPP) after receiving applications for $3.4 million while the target was to raise $1 million only.

Following the strong support from shareholders, Minotaur has decided to increase the size of SPP to $2.1 million, which it plans to spend on the companys fully-owned Australian projects.

“Very gratifying result”[hhmc]
Minotaur chairman Roger Higgins said: “This is a very gratifying result, replicating the recent over-subscribed Placement and signifying shareholders con­fidence in the company and its suite of projects.

“Minotaur will work to invigorate its wholly-owned portfolio and the Board looks forward to realising their potential.”

SPP details[hhmc]
The company has decided to allocate shares to at least 75% of the subscriptions from eligible shareholders with a holding of 10,000 shares or more.

Accordingly, Minotaur will allot 42.3 million new shares at a price of 5 cents a share to raise a total of $2.1 m..

Minotaur Exploration Ltd (ASX:MEP) has scaled back its share purchase plan (SPP) after receiving applications for $3.4 million while the target was to raise $1 million only.

Following the strong support from shareholders, Minotaur has decided to increase the size of SPP to $2.1 million, which it plans to spend on the companys fully-owned Australian projects.

“Very gratifying result”


Minotaur chairman Roger Higgins said: “This is a very gratifying result, replicating the recent over-subscribed Placement and signifying shareholders con­fidence in the company and its suite of projects.

“Minotaur will work to invigorate its wholly-owned portfolio and the Board looks forward to realising their potential.”

SPP details


The company has decided to allocate shares to at least 75% of the subscriptions from eligible shareholders with a holding of 10,000 shares or more.

Accordingly, Minotaur will allot 42.3 million new shares at a price of 5 cents a share to raise a total of $2.1 million, which will be in addition to the $4.05 million raised through the recently completed placement.

Allotment of the new securities is scheduled on September 28, 2020, and application funds exceeding those retained from each shareholder will be returned in line with the stated scale back policy by mail on October 1, 2020.

Use of funds


MiRead More – Source

Continue Reading

Australia

MMJ Group Holdings set to capitalise on WeedMD investment as company scales up

MMJ Group Holdings Ltd (ASX:MMJ) (OTCMKTS:MMJJF) is focused on adding to its portfolio of investments in the cannabis value chain in Australia, Canada and Europe.

The addition of WeedMD Inc. (CVE:WMD) (OTCMKTS:WDDMF) (FSE:4WE) in September 2019 is proving to be valuable, with the company producing cannabis products for both the medicinal and adult-use markets in Canada across its three branches – StarSeed Medical Inc, Color Cannabis and CX Industries.

WeedMe announced a C$2.5 million capital raising in March 2020 which strengthened its balance sheet to support its growth plans.

StarSeed Medical Inc[hhmc]
The unique direct-to-consumer medical platform StarSeed Medical is the market leader in insured medical cannabis.

StarSeed focuses on captive patients with benefits plans and insurers to launch customized insured medical cannabis programs to uniquely pair a care service model with medical-grade cannabis.

This targets valuable and overlooked medical channel sales with a closed-loop..

MMJ Group Holdings Ltd (ASX:MMJ) (OTCMKTS:MMJJF) is focused on adding to its portfolio of investments in the cannabis value chain in Australia, Canada and Europe.

The addition of WeedMD Inc. (CVE:WMD) (OTCMKTS:WDDMF) (FSE:4WE) in September 2019 is proving to be valuable, with the company producing cannabis products for both the medicinal and adult-use markets in Canada across its three branches – StarSeed Medical Inc, Color Cannabis and CX Industries.

WeedMe announced a C$2.5 million capital raising in March 2020 which strengthened its balance sheet to support its growth plans.

StarSeed Medical Inc


The unique direct-to-consumer medical platform StarSeed Medical is the market leader in insured medical cannabis.

StarSeed focuses on captive patients with benefits plans and insurers to launch customized insured medical cannabis programs to uniquely pair a care service model with medical-grade cannabis.

This targets valuable and overlooked medical channel sales with a closed-loop model which provides exclusive access to around 350,000-plus potential patients, offering patient-centred cannabis as a service.

Color Cannabis


The Color Cannabis brand consists of a range of distinctive products cultivated with care in the adult-use market.

WeedMD is focused on building brand awareness via promotional tools that trigger interaction, drive awareness and inspire trial at retail and online.

With the exclusive launch of renowned strain Black Sugar Rose, the introduction of a vaporization (vape) and pre-roll line, as well as new nitrogen-infused packaging, the company is executing on its commercial growth plans.

The closed loop medical system offers patient-centred cannabis as a service.

MMJs investment


MMJs investment in WeedMD now comprises:

a) C$6 million in 8.5% unsecured convertible debenture units issued by WeedMD which MMJ has the option to convert into 3.75 million shares by September 25, 2022 (the debenture units have preference over ordinary shares with interest paid to MMJ on quarterly basis); and

b) Warrants that allow MMJ to acquire an additional 3.75 million shares for C$1.80 each by September 25, 2022.

The group is well-placed to capitalise on WeedMDs focus on growth of its indoor and outdoor cultivation, combined with in-house extraction, product development and manufacturing capabilities.

WeedMD is optimized to grow at scale with the ability to expand to double the current size with modest incremental capexRead More – Source

Continue Reading

Australia

Manganese producers set to strike gold after Tesla unveils shift to new generation of batteries

Manganese producers are set to strike the proverbial pot of gold after the world's biggest electric car maker, Tesla Inc (NASDAQ:TSLA) (FRA:TL0) announced a major shift in its battery strategy – the move to manufacture its own batteries incorporating manganese and nickel.

Tesla's aim to drive down the cost of its electric cars will see the company producing its own new generation of batteries that will be more powerful, longer-lasting and half as expensive than the companys current cells.

More power and greater range[hhmc]
Teslas new larger cylindrical cells will provide five times more energy, six times more power and far greater driving range, according to Tesla chief executive officer Elon Musk.

Full production is about three years away, Musk said at Teslas Battery Day on Wednesday.

Manufacture own batteries[hhmc]

We intend to increase, not reduce battery cell purchases from Panasonic, LG & CATL (possibly other partners too). However, even with our cell suppliers goin..

Manganese producers are set to strike the proverbial pot of gold after the world's biggest electric car maker, Tesla Inc (NASDAQ:TSLA) (FRA:TL0) announced a major shift in its battery strategy – the move to manufacture its own batteries incorporating manganese and nickel.

Tesla's aim to drive down the cost of its electric cars will see the company producing its own new generation of batteries that will be more powerful, longer-lasting and half as expensive than the companys current cells.

More power and greater range


Teslas new larger cylindrical cells will provide five times more energy, six times more power and far greater driving range, according to Tesla chief executive officer Elon Musk.

Full production is about three years away, Musk said at Teslas Battery Day on Wednesday.

Manufacture own batteries

We intend to increase, not reduce battery cell purchases from Panasonic, LG & CATL (possibly other partners too). However, even with our cell suppliers going at maximum speed, we still foresee significant shortages in 2022 & beyond unless we also take action ourselves.

— Elon Musk (@elonmusk) September 21, 2020

Tesla aims to manufacture its own battery cells at several highly automated factories around the world and source its own raw materials, including manganese.

Musk disclosed several technological advances that it plans to implement to substantially lower the cost of producing lithium-ion batteries and electric vehicles.

This plan includes to start manufacturing at a very large scale, an innovative type of lithium-ion battery with a cathode that contains around 33% manganese, made directly from manganese metal.

Affordable electric car


The switch is aimed at delivery an 'affordable' electric car by slashing battery costs in half with new technology and processes.

Building an affordable electric car “has always been our dream from the beginning of the company”, Musk told an online audience of more than 270,000.

In January, Musk had said that in order to ramp-up production of the Tesla Model Y vehicle, introduce the new Cybertruck and launch its semi-electric truck, a lot more batteries would be needed.

“The thing were going to be really focused on is increasing battery production capacity because thats very fundamental – because if you dont improve battery production capacity, then you end up just shifting unit volume from one product to another and you havent actually produced more electric vehicles,” Musk said.

Euro Manganese shares soar


Euro Manganese Inc (ASX:EMNRead More – Source

Continue Reading

Trending